Demyelinating Diseases
Recent clinical, regulatory, research and industry developments relating to this disease.
Remyelination protects neurons from DLK-mediated neurodegeneration.
Myelination of the nervous system: mechanisms and functions.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Demyelinating Diseases3
- Apoptosis1
- Cuprizone1
- MAP Kinase Kinase Kinases1
- Multiple Sclerosis1
- Neuroinflammatory Diseases1
- Neurons1
- Remyelination1
Leading journals5
- Annual review of cell and developmental biology1
- International journal of molecular sciences1
- Journal of immunology (Baltimore, Md. : 1950)1
- Molecular neurodegeneration1
- Nature communications1
Leading researchers8
- Abdelhak A1
- Aicher SA1
- Ananth K1
- Assinck P1
- Caprariello AV1
- Cordano C1
- Dufour JH1
- Duncan GJ1
Affiliations (unnormalised)6
- Casey Eye Institute1
- Center for Immunology and Inflammatory Diseases1
- Centre for Regenerative Medicine1
- Cliniques Universitaires Saint-Luc1
- Department of Clinical Neurosciences1
- Institute of NeuroScience1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Demyelinating diseases are disorders characterized by loss or dysfunction of myelin in the central or peripheral nervous system. The supplied material frames them as conditions in which myelin biogenesis, maintenance, and clearance are disrupted, leading to impaired axonal function and injury.
Some demyelinating injury can be chemically induced, as illustrated by cuprizone, a copper chelator that induces demyelination in specific brain structures. The grounding also supports inflammatory and cellular injury mechanisms, including damage from oligodendrocyte dysfunction, astrocytes, microglia, peripheral immune cells, and reduced myelin protein synthesis or mitochondrial dysfunction in oligodendrocytes.
Myelin normally enables fast saltatory impulse propagation and supports axonal integrity through metabolic and trophic coupling between glia and axons. In demyelinating disease, loss of myelin disrupts this axoglial symbiosis, exposes axons to inflammatory and oxidative stress, and can be accompanied by nodal/paranodal disruption, oligodendrocyte death, impaired myelin biogenesis, and defective myelin clearance by microglia/macrophages.
The grounding supports exposure to cuprizone as a factor that can induce demyelination experimentally. It also indicates that inflammatory states involving microglia, astrocytes, peripheral immune cells, and oxidative stress are associated with demyelinating injury, but does not provide broader clinical risk factors.
AI-generated summary grounded in MeSH and 3 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.